Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
12 studies found for:    stx209
Show Display Options
Download search resultsDownload the search results for:
stx209 (12 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
2 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
3 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
4 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
5 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
6 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
7 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
8 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
9 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209
10 Completed Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
Condition: Fragile X Syndrome
Intervention: Drug: STX209
11 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
12 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen

Indicates status has not been verified in more than two years